PMID- 25352401
OWN - NLM
STAT- MEDLINE
DCOM- 20161220
LR  - 20220325
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Print)
IS  - 1043-3074 (Linking)
VI  - 38
IP  - 3
DP  - 2016 Mar
TI  - Phase I study of vandetanib with radiation therapy with or without cisplatin in 
      locally advanced head and neck squamous cell carcinoma.
PG  - 439-47
LID - 10.1002/hed.23922 [doi]
AB  - BACKGROUND: Vandetanib, added to cisplatin and radiation therapy (RT) overcomes 
      chemoradiation therapy (CRT) and epidermal growth factor receptor (EGFR) 
      inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and 
      models. METHODS: Patients with previously untreated HNSCC received vandetanib 
      daily for 14 days (starting dose 100 mg) and then vandetanib + RT (2.2 Gy/day, 5 
      days/week) for 6 weeks (regimen 1) or vandetanib + RT (2 Gy/day, 5 days/week) + 
      cisplatin (30 mg/m(2) weekly) for 7 weeks (regimen 2). The primary objective was 
      the maximum tolerated dose (MTD) of vandetanib with RT +/- cisplatin. RESULTS: Of 
      33 treated patients, 30 completed therapy (regimen 1, n = 12; regimen 2, n = 18). 
      MTD in regimen 2 was 100 mg (3 dose limiting toxicities [DLTs] at 200 mg), 
      whereas regimen 1 was stopped because of poor recruitment (1 DLT at 200 mg). Most 
      common grade >/=3 adverse events (AEs) were dysphagia (30%), stomatitis (33%), and 
      mucosal inflammation (27%). Five patients discontinued vandetanib because of AEs. 
      CONCLUSION: Vandetanib with CRT was feasible.
CI  - (c) 2015 Wiley Periodicals, Inc.
FAU - Papadimitrakopoulou, Vasiliki A
AU  - Papadimitrakopoulou VA
AD  - Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Frank, Steven J
AU  - Frank SJ
AD  - Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
FAU - Cohen, Ezra W
AU  - Cohen EW
AD  - Department of Medicine, University of Chicago, Chicago, Illinois.
FAU - Hirsch, Fred R
AU  - Hirsch FR
AD  - University of Colorado Cancer Center, Aurora, Colorado.
FAU - Myers, Jeffrey N
AU  - Myers JN
AD  - Department of Head and Neck Surgery, University of Texas, MD Anderson Cancer 
      Center, Houston, Texas.
FAU - Heymach, John V
AU  - Heymach JV
AD  - Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Lin, Heather
AU  - Lin H
AD  - Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas.
FAU - Tran, Hai T
AU  - Tran HT
AD  - Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, 
      Houston, Texas.
FAU - Chen, Changhu R
AU  - Chen CR
AD  - Department of Radiation Oncology, University of Toledo, Toledo, Ohio.
FAU - Jimeno, Antonio
AU  - Jimeno A
AD  - Division of Medical Oncology, Department of Medicine, University of Colorado, 
      Aurora, Colorado.
FAU - Nedzi, Lucien
AU  - Nedzi L
AD  - Department of Radiation Oncology, Southwestern Medical Center, Dallas, Texas.
FAU - Vasselli, Joseph R
AU  - Vasselli JR
AD  - AstraZeneca Pharmaceuticals, Wilmington, Delaware.
FAU - Lowe, Elizabeth S
AU  - Lowe ES
AD  - AstraZeneca Pharmaceuticals, Wilmington, Delaware.
FAU - Raben, David
AU  - Raben D
AD  - Department of Oncology, University of Colorado, Aurora, Colorado.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA097007/CA/NCI NIH HHS/United States
GR  - UL1 TR000371/TR/NCATS NIH HHS/United States
GR  - P50 CA097007 10/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20150616
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - 0 (Piperidines)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - Q20Q21Q62J (Cisplatin)
RN  - YO460OQ37K (vandetanib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carcinoma, Squamous Cell/drug therapy/radiotherapy/*therapy
MH  - Chemoradiotherapy/*methods
MH  - Cisplatin/administration & dosage
MH  - Female
MH  - Head and Neck Neoplasms/drug therapy/radiotherapy/*therapy
MH  - Humans
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Middle Aged
MH  - Piperidines/administration & dosage
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Quinazolines/administration & dosage
MH  - Squamous Cell Carcinoma of Head and Neck
PMC - PMC4414661
MID - NIHMS639245
OTO - NOTNLM
OT  - cisplatin
OT  - head and neck squamous cell cancer
OT  - radiation therapy
OT  - vandetanib
EDAT- 2014/10/30 06:00
MHDA- 2016/12/21 06:00
PMCR- 2016/03/01
CRDT- 2014/10/30 06:00
PHST- 2014/10/24 00:00 [accepted]
PHST- 2014/10/30 06:00 [entrez]
PHST- 2014/10/30 06:00 [pubmed]
PHST- 2016/12/21 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - 10.1002/hed.23922 [doi]
PST - ppublish
SO  - Head Neck. 2016 Mar;38(3):439-47. doi: 10.1002/hed.23922. Epub 2015 Jun 16.